Paul Varley

Dr. Varley is an expert in biopharmaceutical development with more than 25+ years experience of developing antibodies, proteins and other macromolecules into drugs from Research into the clinic and through to commercialization. Previously Paul held a similar roles in Cambridge Antibody Technology, AstraZeneca, MedImmune and most recently Kymab. Previously Paul had also worked at British Biotech, the UK National Institute of Biological Standards and Control (NIBSC) and the U.S. National Institutes of Health. Dr Varley holds a degree in Biomolecular Sciences (First Class) from Portsmouth Polytechnic and a PhD in Biochemistry from the University of Newcastle upon Tyne.

Paul is a member of the British Pharmacopeia (BP) Commission and Chair of BP Expert Advisory Group on Biological and Biotechnological Products (2013 – 2021). He also currently chairs a MHRA/BP working party on new standards for Biological Medicines (DPS) and is also a member of the European Pharmacopeia (EP) Expert Committee on Monoclonal Antibodies. Paul is also a member of the UK Vaccine Task Force/BIA Manufacturing Advisory Group.

Paul has been involved with many other activities in the Biopharmaceutical / Bioprocessing space including the European Biotech Enterprises (EBE) Biomanufacturing Committee, Bioprocess UK steering group, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotherapeutics group, and BioProNet.

Paul has contributed to many Advisory Boards and related activities during his career including at University of Cambridge Department of Chemical Engineering and Biotechnology, University College London Biochemical Engineering, the UK National Biologics Manufacturing Centre, and the White Rose Universities DTP in Mechanistic Biology.